RVL Pharmaceuticals plc, a specialty pharmaceutical company, announced that Brian Markison, Chief Executive Officer, will present at two upcoming conferences as follows:
BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, will present at two upcoming conferences as follows:
| H.C. Wainwright Global Investment Conference, Miami Beach, FL | |
| Date: | Tuesday, May 24, 2022 |
| Time: | 11:00 a.m. ET |
| Webcast: | Click Here |
| Jefferies Healthcare Conference, New York City, NY | |
| Date: | Thursday, June 9, 2022 |
| Time: | 1:30 p.m. ET |
| Webcast: | Click Here |
The webcasts will be available thereafter via the Company’s website www.rvlpharma.com website under the “Investor & News” section.
About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.
Investor and Media Relations for RVL Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
